PROSCA/BLADDR 2022 | Remaining questions in mHSPC

Silke Gillessen, MD, PhD, University of Lugano and the Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, explores remaining unanswered questions in the management of metastatic hormone-sensitive prostate cancer (mHSPC), including identification of predictive and prognostic biomarkers, as well as treatment de-intensification. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR 2022) in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.